Invictus RG’s Biogen BIIB Stock Holding History

Invictus RG’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-66	Closed	-$21K	–	274
2017 Q3	$21K	Sell	66 -444	-87%	-$131K	0.02%	442
2017 Q2	$138K	Buy	+510	New	+$135K	0.1%	349

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Invictus RG's BIIB Position: Q4 2017 in Review

Invictus RG sold out of Biogen (BIIB) in Q4 2017, closing a stake of 66 shares — an estimated $21K sold.

Invictus RG first reported a position in BIIB in Q2 2017 and held it in 2 quarters. The position peaked at $138K in Q2 2017. 1,123 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

Invictus RG reported no remaining Biogen position as of Q4 2017 after selling out during the quarter.
Invictus RG sold 66 Biogen shares in Q4 2017, an estimated $21K.
Invictus RG first reported a position in Biogen in Q2 2017 and held it in 2 quarters.
Invictus RG's Biogen position peaked at $138K in Q2 2017.
1,123 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on Invictus RG's 13F filing for Q4 2017, filed 13 Feb 2018.